Drug abuse, brain calcification and glutamate-induced neurodegeneration

dc.contributor.authorRodríguez Allué, Manuel José
dc.contributor.authorPugliese, Marco
dc.contributor.authorMahy Gehenne, Josette Nicole
dc.date.accessioned2013-03-18T13:15:26Z
dc.date.available2013-03-18T13:15:26Z
dc.date.issued2009-02
dc.date.updated2013-03-18T13:15:27Z
dc.description.abstractPositive and negative reinforcing systems are part of the mechanism of drug dependence. Drugs with abuse potential may change the manner of response to negative emotional stimuli, activate positive emotional reactions and possess primary reinforcing properties. Catecholaminergic and peptidergic processes are of importance in these mechanisms. Current research needs to understand the types of adaptations that underlie the particularly long-lived aspects of addiction. Presently, glutamate is candidate to play a role in the enduring effects of drugs of abuse. For example, it participates in the chronic pathological changes of corticostriatal terminals produced by methamphetamine. At the synaptic level, a link between over-activation of glutamate receptors, [C(a2+)](i) increase and neuronal damage has been clearly established leading to neurodegeneration. Thus, neurodegeneration can start after an acute over-stimulation whose immediate effects depend on a diversity of calcium-activated mechanisms. If sufficient, the initial insult results in calcification and activation of a chronic on-going process with a progressive loss of neurons. At present, long-term effects of drug dependence underlie an excitotoxicity process linked to a polysynaptic pathway that dynamically regulates synaptic glutamate. Retaliatory mechanisms include energy capability of the neurons, inhibitory systems and cytoplasmic calcium precipitation as part of the neuron-glia interactions. This paper presents an integrated view of these molecular and cellular mechanisms to help understand their relationship and interdependence in a chronic pathological process that suggest new targets for therapeutic intervention.
dc.format.extent14 p.
dc.format.mimetypeapplication/pdf
dc.identifier.idgrec555306
dc.identifier.issn1874-4737
dc.identifier.urihttps://hdl.handle.net/2445/34290
dc.language.isoeng
dc.publisherBentham Science Publishers
dc.relation.isformatofVersió postprint del document publicat a: http://dx.doi.org/10.2174/1874473711205040004
dc.relation.ispartofCurrent Drug Abuse Reviews, 2009, vol. 2, num. 1, p. 99-112
dc.relation.urihttp://dx.doi.org/10.2174/1874473711205040004
dc.rights(c) Bentham Science Publishers, 2009
dc.rights.accessRightsinfo:eu-repo/semantics/openAccess
dc.sourceArticles publicats en revistes (Ciències Fisiològiques)
dc.subject.classificationÀcid glutàmic
dc.subject.classificationAminoàcids
dc.subject.classificationMalalties neurodegeneratives
dc.subject.classificationDrogues
dc.subject.otherGlutamic acid
dc.subject.otherAmino acids
dc.subject.otherNeurodegenerative Diseases
dc.subject.otherDrugs of abuse
dc.titleDrug abuse, brain calcification and glutamate-induced neurodegeneration
dc.typeinfo:eu-repo/semantics/article
dc.typeinfo:eu-repo/semantics/acceptedVersion

Fitxers

Paquet original

Mostrant 1 - 1 de 1
Carregant...
Miniatura
Nom:
555306.pdf
Mida:
9.68 MB
Format:
Adobe Portable Document Format